RT info:eu-repo/semantics/article
T1 Is the conjunctiva a potential target for advanced therapy medicinal products?
A1 Diebold Luque, María Yolanda
A1 García Posadas, Laura
K1 Oftalmología
K1 Advanced therapies
K1 Conjunctiva
K1 Tissue engineering
K1 Terapias avanzadas
K1 Conjuntiva
K1 Ingeniería Tisular
K1 3201.09 Oftalmología
AB The conjunctiva is a complex ocular tissue that provides mechanical, sensory, and immune protection for the ocular surface. It is affected by many diseases through different pathological mechanisms. If a disease is not treated and conjunctival function is not fully restored, the whole ocular surface and, therefore, sight is at risk. Different therapeutic approaches have been proposed, but there are still unsolved conjunctival alterations that require more sophisticated therapeutic options. Advanced therapy medicinal products (ATMPs) comprise a wide range of products that includes cell therapy, tissue engineering, and gene therapy. To the best of our knowledge, there is no commercialized ATMP specifically for conjunctival treatment yet. However, the conjunctiva can be a potential target for ATMPs for different reasons. In this review, we provide an overview of the advances in experimental phases of potential ATMPs that primarily target the conjunctiva. Important advances have been achieved through the techniques of cell therapy and tissue engineering, whereas the use of gene therapy in the conjunctiva is still marginal. Undoubtedly, future research in this field will lead to achieving commercially available ATMPs for the conjunctiva, which may provide better treatments for patients.
PB MDPI
YR 2021
FD 2021
LK https://uvadoc.uva.es/handle/10324/65031
UL https://uvadoc.uva.es/handle/10324/65031
LA eng
NO Pharmaceutics, 2021, vol. 13, n. 8, 1140
NO Producción Científica
DS UVaDOC
RD 17-jul-2024